U
TTPH

UBS’s Tetraphase Pharmaceuticals, Inc. TTPH Stock Holding History

UBS’s Portfolio TTPH Stock Details TTPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		$10K Buy
+25
New +$6.7K ﹤0.01% 8863

Other funds holding TTPH

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
CPIM
Columbia Partners Investment Management Alexandria, Virginia $257M AUM 8.17% 1-Year Est. Return

UBS's TTPH Position: Q3 2014 in Review

UBS reduced its Tetraphase Pharmaceuticals, Inc. (TTPH) stake by 60% in Q3 2014, selling an estimated $17.1K and leaving 43 shares worth $17K. The position accounts for ﹤0.01% of the portfolio, ranked #8229.

UBS first reported a position in TTPH in Q3 2013 and has held it in 5 quarters since. The position peaked at $29K in Q2 2014. 73 funds tracked by Wall St. Rank hold TTPH as of Q3 2014.

  • UBS held 43 shares of Tetraphase Pharmaceuticals, Inc. worth $17K as of Q3 2014.
  • UBS sold 64 Tetraphase Pharmaceuticals, Inc. shares in Q3 2014, an estimated $17.1K.
  • Tetraphase Pharmaceuticals, Inc. made up ﹤0.01% of UBS's portfolio in Q3 2014, its #8229 holding.
  • UBS first reported a position in Tetraphase Pharmaceuticals, Inc. in Q3 2013 and has held it in 5 quarters since.
  • UBS's Tetraphase Pharmaceuticals, Inc. position peaked at $29K in Q2 2014.
  • 73 funds tracked by Wall St. Rank held Tetraphase Pharmaceuticals, Inc. as of Q3 2014.

Based on UBS's 13F filing for Q3 2014, filed 12 Nov 2014.